Cartalax
Bioregulatory Tripeptide | Cartilage & Connective Tissue Support
On this page
What is Cartalax?
Cartalax is a lab-made three-amino-acid peptide (a tripeptide) from the Khavinson bioregulator family, originally identified in kidney tissue and studied mainly in Russian-language research literature. Researchers have looked at its effects on cartilage- and connective-tissue cells in animal and cell-culture studies. It's sold here strictly for laboratory research use, not for use in people or animals.
Key terms:
Cartalax is a synthetic tripeptide.
Cartalax (AED peptide, T-31) is a lab-made peptide of three amino acids: alanine, glutamate, and aspartate. Professor Vladimir Khavinson developed it as part of the bioregulator peptide family. It was first isolated from kidney tissue, and the same sequence appears in the alpha-1 chain of type XI collagen. Research reports it may support cartilage, connective tissue, and cell regeneration. It appears to work by changing markers of cell growth and the pathways that tell cells to self-destruct.
Key research areas
- Capsule form studied in Russian research for joint and connective-tissue applications
- Used in Russian clinical practice for degenerative conditions, per regional research literature
- Safety profile reported in Russian bioregulatory-peptide research
Researched dosing
This table reflects the oral-capsule dosing schedules described in Russian research and manufacturer literature for Cartalax, presented as research-methodology reference, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Standard study protocol | 1 capsule (100mcg) | Daily with meals | Oral |
| Higher-dose studies | 2 capsules (200mcg) | Daily with meals | Oral |
| Maintenance | 1 capsule (100mcg) | Every other day with food | Oral |
Commonly cycled 12 weeks on, 12+ weeks off.
How it works
This section is drawn from the original Russian-language research describing how Cartalax is formulated as an oral capsule intended to survive digestion — it covers dosage-form design rather than a typical cell-signaling explanation.
Each capsule contains 0.1mg (100mcg) of AC-4 peptide complex. Specialized formulation designed to survive digestion and provide systemic bioregulatory effects.
Research applications
This section lists the research areas — mainly joint and connective-tissue studies in animal and cell-culture models — that scientists have investigated for Cartalax; a summary of Russian-language research literature, not medical claims about people.
Joint Health
Russian studies report benefits for osteoarthritis and osteochondrosis using 0.1mg capsules, including research use aimed at degenerative processes in elderly populations, and reported effects on healing after bone and joint injuries.
Dosage reference
- Doses used in research
- 1–2 capsules (100–200 mcg total)
- Frequency in studies
- 1-2 times daily with meals
- Handling
- Reconstituted solution — research use only; not for administration
- Timeline reported in studies
- Joint improvements: 3-4 weeks, Full benefits: 2-3 months
- Storage
- Room temperature in dry place
- Cycle length
- 1-3 months
- Break between cycles
- 3-6 months between courses
Interactions
This list shows which other Khavinson-family peptides and joint-support compounds are studied alongside Cartalax, and why.
Reconstitution & storage
Cartalax is studied and supplied in capsule form rather than as an injectable powder, so there's no water-based mixing step — this section notes handling and storage rather than reconstitution.
- Each capsule contains 0.1mg (100mcg) of active peptide complex
- Do not open or chew capsules
- Follow official Russian manufacturer instructions for optimal results
- Store the reconstituted solution refrigerated (2–8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: Room temperature, cool dry place, use within As per manufacturer dating
Reconstituted: 2-6°C, use within N/A - oral capsule form
Open the Cartalax reconstitution calculatorQuality indicators
These are the packaging and labeling checks researchers use to help confirm a Cartalax capsule product is genuine and correctly dosed.
Pharmaceutical packaging - Russian pharmaceutical products come in professional packaging with holographic seals
Correct capsule content - Each capsule should contain exactly 0.1mg (100mcg) of AC-4 peptide complex
Clear dosing instructions - Legitimate products include detailed Russian/English instructions specifying "with meals"
Import verification - Ensure proper import documentation for authenticity
Manufacturer compliance - Follow official Russian manufacturer timing guidelines for safety and efficacy
What to expect
This timeline reflects what the Russian-language research literature reports at each stage of a study — research context for comparing studies, not a personal-results promise.
No significant changes, establishing baseline
Gradual improvement in joint comfort
Noticeable mobility improvements
Maximum therapeutic effect achieved
Safety notes
This section covers handling cautions and regulatory notes for Cartalax — it is not FDA-approved, and available safety data comes primarily from Russian research literature rather than Western clinical trials.
- Take with meals as directed by Russian manufacturers to optimize tolerance
- Russian pharmaceutical product - not approved by FDA
- No reported side effects in Russian clinical use when taken properly
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only — not for human or veterinary use.
Community data
Community Insights
Based on data the community reported. Not clinical proof.
References
Cartalax, along with other Khavinson peptides, stimulated proliferation and neurogenic differentiation of stem cells, indicating broader regenerative potential beyond connective tissue.
Cartalax influenced aging-related gene expression in bone marrow mesenchymal stem cells, potentially maintaining regenerative capacity in both proliferating and stationary phase cells.
Demonstrated reduction in pro-apoptotic p53 expression in aging kidney cells, potentially extending cellular lifespan and maintaining tissue integrity through decreased programmed cell death.